Twist Bioscience Sees AI Drug Discovery Pipeline Expand

Twist Bioscience Corporation (NASDAQ: TWST ) stock is up on Monday as the company reported its fiscal 2026 third-quarter financial results and raised fiscal 2026 guidance. The life science company reported an adjusted loss of 56 cents per share, missing the consensus loss of 50 cents. The sales came in at $118.376 million, up 23% year over year, beating the consensus of $114.49 million and the management guidance of $114 million-$115 million. • Twist Bioscience stock is showing exceptional strength. What’s behind TWST gains? DNA Synthesis and NGS Businesses Continue To Grow "Well into our final quarter of the fiscal year, we remain confident in our trajectory and continue to expect to achieve adjusted EBITDA breakeven this quarter. That milestone is not the destination. It’s the foundation for delivering disciplined execution and profitable growth as we move through fiscal...